The longest dosing interval in HAE attack prophylaxis1,2

At-home dosing every 4 or 8 weeks with a convenient autoinjector1,2

Not actual size.

Dosing1:

  • Recommended dosage: DAWNZERA 80 mg SC every 4 weeks
  • DAWNZERA 80 mg SC every 8 weeks may also be considered

If a dose is missed, advise patients to take DAWNZERA as soon as possible and then take their next dose 4 or 8 weeks later, as prescribed.1

Control without added complexity

Refrigeration icon. Refrigeration icon.
DAWNZERA can be stored at room temperature1
  • Refrigeration is recommended
  • Can be stored up to 86 °F (30 °C) for up to 6 weeks*

*If not used within the 6 weeks stored at room temperature, discard DAWNZERA.

Clock icon with an arrow around it. Clock icon with an arrow around it.
Only 10 seconds to inject each 0.8 mL dose1
A beaker icon with a slash through it. A beaker icon with a slash through it.
DAWNZERA contains no citric acid, which is associated with injection-site pain1,3†

Help your patients learn how to receive and administer DAWNZERA

See the Patient Injection Training video

HAE=hereditary angioedema; SC=subcutaneous.

†In clinical studies, injection-site reactions, including injection-site pain, were the most frequently reported adverse reactions with DAWNZERA.1

See other areas to explore for DAWNZERA:

See the switch protocol Get patients started

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

DAWNZERA is contraindicated in patients with a history of serious hypersensitivity reactions, including anaphylaxis, to donidalorsen or any of the excipients in DAWNZERA.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis, have been reported in patients treated with DAWNZERA. If signs and symptoms of serious hypersensitivity reactions occur, discontinue DAWNZERA and institute appropriate therapy.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥ 5%) are injection site reactions, upper respiratory tract infection, urinary tract infection, and abdominal discomfort.

INDICATION

DAWNZERA (donidalorsen) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Please see full Prescribing Information for DAWNZERA.

References: 1. DAWNZERA. Prescribing information. Ionis Pharmaceuticals. 2. Khatri H, Estepa P, Cummings B. Participant reported ease-of-use with a prefilled, single-dose, disposable autoinjector for the treatment of hereditary angioedema. J Allergy Clin Immunol. 2025;155(2 suppl);AB228. 3. Junker S, Ebert O, Bartsch R. A systematic literature review of injection site pain perception in adult patients treated with citrate-free and citrate-containing biologic agents. Curr Rheumatol Rev. 2023;19(3):303-313. doi:10.2174/1573397118666220829123713